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L-Arginine counteracts nitric oxide deficiency and improves plication with uncertain outcome, ranging from complete
the recovery phase of ischemic acute renal failure in rats. restitution to high mortality [1]. Ischemia, followed by
Background. In ischemic acute renal failure (ARF), nitric reperfusion, is one of the major causes of ARF [2]. Re-oxide–dependent regulation of renal hemodynamics and glo-
cent studies clearly indicate that nitric oxide is funda-merular function is disturbed. Previous studies indicate that
mentally involved in the regulation of renal hemodynam-the nitric oxide precursor l-arginine (l-Arg) has beneficial
effects on renal function. Here we further analyzed the impact ics and homeostasis [3, 4], and that nitric oxide pathways
of l-Arg on functional and biochemical parameters of nitric are disturbed in ARF [5]. Thus, decreased nitric oxide
oxide signaling during the course of ischemic ARF. activity may be causally linked to ARF.Methods. Ischemic ARF was induced in rats by bilateral
Nitric oxide is generated from l-arginine (l-Arg) byclamping of renal arteries for 45 minutes. l-Arg was applied
nitric oxide synthases (NOS) [6]. Three different NOSintraperitoneally during clamping, and orally during 14 days
of follow-up. Glomerular filtration rate (GFR) and renal have been detected [neuronal NOS (nNOS), inducible
plasma flow (RPF) were measured, and biochemical parame- NOS (iNOS), and endothelial NOS (eNOS)], which have
ters analyzed by protein immunoblots.
all been identified in the kidney [7–9]. The major nitricResults. Clamping resulted in 70% to 90% reduction of GFR
oxide receptor, soluble guanylate cyclase [10, 11], con-and RPF, with a gradual recovery by day 14. Using an in
situ assay with the oxidative fluorescent dye hydroethidine, sists of two subunits  and  [12]. Nitric oxide alters its
increased tubular generation of O2 was detected in the early heme moiety and causes activation of the enzyme [13],
course of ischemic ARF, indicating enhanced oxidative stress. followed by a rise in cyclic guanosine monophosphate
These findings were accompanied by up-regulation of the nitric
(cGMP) levels [14]. cGMP further mediates the nitricoxide receptor, soluble guanylate cyclase, and by significant
oxide effector cascade by stimulating or inhibiting cer-regulatory changes of inducible nitric oxide synthase (iNOS)
and endothelial NOS expression. l-Arg had a beneficial effect tain phosphodiesterases, modulating cation ion channels,
on GFR and RPF, decreased O2 production, diminished up- or activating cGMP-dependent protein kinases (cGK-I
regulation of soluble guanylate cyclase, and prevented up-regu- and cGK-II) [15].lation of iNOS.
The Km value of l-Arg for saturation of eNOS is 3 toConclusion. Ischemic ARF is accompanied by marked alter-
5 mol/L [16], well below extra- and intracellular l-Argations in the expression of key enzymes of the nitric oxide
pathway, indicative for deficiency of constitutive NOS activity. concentrations [17, 18]. However, clinical studies and
l-Arg supplementation reduces O2 generation and signifi- animal models provide evidence that supplementation of
cantly improves the expression of nitric oxide signaling proteins l-Arg has beneficial effects in diseases such as pulmonaryas well as the recovery phase of ischemic ARF.
hypertension [19], heart failure [20], and endothelial dys-
function [21]. Furthermore, in a recent publication from
our group, we detected significantly reduced tissue l-ArgAcute renal failure (ARF) is a common clinical com-
levels in an animal model of toxic ARF [22]. Although
tissue l-Arg levels in this model of ARF were still above
the Km value for saturation of NOS, supplementationKey words: renal failure, l-arginine, ischemia/reperfusion injury, hy-
droethidine, nitric oxide, superoxide. of l-Arg had beneficial effects for kidney function [22].
This phenomenon has been described as the “l-Arg par-Received for publication October 6, 2002
adox” [23].and in revised form December 26, 2002
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failure [24], but only limited information is available on prophylaxis of pain, tramadol (2.0 mg/kg body weight)
prolonged effects of l-Arg on ischemic ARF and on was applied subcutaneously.
the downstream cascade of nitric oxide. Therefore, we l-Arg group (bilateral clamping and supplementation
analyzed the impact of l-Arg supplementation on kidney with l-Arg). Identical procedure was performed as de-
function during the recovery phase of ischemic ARF scribed for clamping group, except interperitoneal sup-
over 14 days. For this purpose, we induced renal ischemia plementation of l-Arg (500 mg/kg body weight) in 0.5
in a rat model by bilateral clamping of renal arteries, mL 0.9% NaCl after 15 minutes of arterial clamping.
followed by reperfusion. Supplementation of l-Arg was During the follow-up period, l-Arg was added to tap
started within the phase of ischemia and was continued water (1%) [25].
throughout the follow-up period of 14 days. Kidney func- To control for effects resulting from protein supple-
tion was monitored by measuring glomerular filtration mentation, the stereoisomeric d-Arg l-aspartate (d-Arg)
rate (GFR) and renal plasma flow (RPF). The renal was used in the same manner as l-Arg. In order to apply
expression of NOS, nitric oxide receptor soluble guanylyl comparable concentrations of d-Arg, preliminary dose
cyclase, cGMP-dependent protein kinase (cGK-I), and finding experiments analyzing the pharmacokinetics of
O2 generation visualized with hydroethidine fluores- oral and intraperitoneal supplementation of l-Arg and
cence using confocal laser scan microscopy were deter-
d-Arg were performed as described below.mined.
Sham group (sham-operation and supplementation with
saline). Identical procedure was performed as described
METHODS for clamping group, except that in these animals no
clamping of renal arteries was performed. A dose ofDrugs
0.9% NaCl (0.5 mL) were applied intraperitoneally afterl-Arg, d-arginine (d-Arg), l-aspartic acid (l-Asp),
15 minutes of arterial clamping.l-arginine l-aspartic acid (l-Arg), d-arginine l-aspartic
Control group (untreated animals). Animals with noacid (d-Arg) paraformaldehyde, and hydroethidine were
previous treatment performed were investigated. Thesefrom Sigma Chemical Co. (St. Louis, MO, USA). Fluo-
animals reflect day 0.rescence-inulin and paraminohippuric acid (PAH) were
The care of animals and experimental procedures per-from ICN Pharmaceuticals, Inc. (Costa Mesa, CA, USA),
formed in this study were in accordance with the Germantramadol (Tramal) was from Gru¨nenthal (Aachen, Ger-
many), xylacin hydrochloride (Rompun) was from Bayer law for animal protection.
(Leverkusen, Germany), and ketamine (Ketanest) was
Pharmacokinetics and effects on blood pressurefrom Pharmacia & Upjohn (Erlangen, Germany). If not
indicated otherwise, all drugs were further diluted in 0.9% Left femoral artery and vein of anesthetized rats were
NaCl (wt/vol). prepared. Arterial blood pressure was measured using
a pressure transducer (Hellige Recomed, Freiburg i. Br.,Experimental procedure
Germany), which was placed in the cannulated femoral
Female Sprague-Dawley rats (200 to 250 g body artery. Values of mean arterial pressure (MAP) and
weight) were obtained from Charles River (Kissleg, Ger- heart rate were recorded continuously for 6 hours to
many). After a period of at least 24 hours in cages within exclude hemodynamic effects of the l-Arg application
a temperature-controlled room with 12–12-hour light- on MAP or heart rate. Blood samples were taken as
dark cycle, standard food with free access to drinking control prior to application of any substance, and at 6
water, anesthesia was performed by intraperitoneal ap- time points thereafter. Enteral application of l-Arg and
plication of xylacin hydrochloride (10 mg/kg body weight)
d-Arg was performed via direct gastric infusion afterand ketamine (100 mg/kg body weight). All operative
laparatomy. Fluid loss was prevented by immediate clo-procedures were performed on thermoregulated heating
sure of wounds. All blood samples were commerciallyboards to maintain body temperature at 37.5C. Animals
analyzed by Bioscientia (Ingelheim, Germany) withwere divided into the following subgroups.
high-performance liquid chromatography (HPLC) anal-Clamping group (bilateral clamping and supplementa-
ysis for serum concentrations of l-Arg and d-Arg intion with saline). Both kidneys were prepared carefully
order to calculate pharmacokinetics.by a bilateral flank incision. Renal arteries were prepared
and temporarily ligated on both sides in order to start
Measurement of inulin and PAH clearanceclamping with microclips simultaneously. Dispensable
For estimation of GFR and RPF, inulin and PAHfluid loss was prevented by closing wounds with sterile
clearances were determined. The left femoral vein wasstrips during the clamping phase. Intraperitoneal appli-
cannulated with a PE-10 (polyethylene) catheter. Inulincation of 0.5 mL 0.9% NaCl was started 15 minutes after
and PAH (1 mg of each substance solved in 0.25 mLclamping. Following the clamping period, both micro-
0.9% NaCl) were applied as a bolus injection, followedclips were removed and sutures of muscular layers and
skin were made to close the wound. For postoperative by constant infusion of both substances (inulin 5 mg/hour,
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PAH 5 mg/hour) using a Secura FT perfusor (B. Braun, luted 1:200), rabbit soluble guanylyl cyclase subunit 
(diluted 1:1000) and soluble guanylyl cyclase subunit Melsungen, Germany). After suprapubic incision, the
(diluted 1:1000) polyclonal antibodies were a kind gifturine bladder was cannulated with a PE-50 (polyethyl-
of Dr. Zabel [11]. Blots were subsequently incubatedene) catheter to measure urine flow and obtain urine
with horseradish peroxidase-conjugated anti-rabbit IgGsamples. When reaching a steady state after 30 minutes
(1:2000, Dako, Hamburg, Germany) and were developedof infusion, urine was collected for 20 minutes and blood
using a chemiluminescence kit (ECL Plus) following thesamples were drawn subsequently. Samples were centri-
manufacturer’s instruction (Amersham Pharmacia Bio-fuged and stored at –20C. Inulin concentrations in urine
tech, Buckinghamshire, UK). Blots were analyzed densi-and plasma were determined by fluorescence spectrome-
tometrically using the Quantity One software (Bio-Radtry. PAH concentrations were measured by photospec-
Laboratories, Philadelphia, PA, USA). To describe vari-trometry (Dynatech Lab, Guernsey, UK) using the an-
ation of expressional changes in the different blots, val-throne method. Calculations of GFR and RPF were
ues were expressed in percentages of the respective shamperformed according to the equations:
group as defined in the legend of each figure.
GFR  (IU * VU) / (IP * t)
Oxidative fluorescent microscopy
and The oxidative fluorescent dye hydroethidine was used
to evaluate in vitro production of superoxide (O2 ) [27].RPF  (UPAH * VU) / (PPAH * t)
Hydroethidine is oxidized to ethidiumbromide (EtBr)
where IU is inulin concentration in urine; UPAH is PAH selectively by O2 and is freely permeable to cells where
concentration in urine; IP is inulin concentration in it is trapped by intercalating with the DNA [28]. When
plasma; PPAH is PAH concentration in plasma; VU is urine oxidized, EtBr is excited at 488 nm with an emission
volume; and t is time of measurement. spectrum of 610 nm.
Animals, anesthetized as described before, received
Organ preparation and tissue harvesting 50 g/100 g body weight hydrothidine (diluted in 10%
After drawing blood samples, both kidneys were per- dimethylsulfoxide in PBS 500 L/100 g body weight)
fused under pressure-controlled conditions (100 mm Hg) intravenously [injected into the cannulated femoral vein
with either ice-cold 0.9% NaCl for 20 seconds for West- for 30 minutes using a Secura FT perfusor (B. Braun)].
ern blot analysis, or paraformaldehyde 4% in phosphate- After 30 minutes of equilibration, animals were sacri-
ficed. Tissue was harvested and organs were fixed asbuffered saline (PBS) for hydroethidine fluorescence
described before, and shock-frozen in liquid nitrogen.confocal laser microscopy. Kidneys were removed, and
Cryoprotected frozen kidney sections (5 m) were pre-for some experiments, dissected into cortex, medulla
pared and immediately scanned using a MRC-1024 laser(outer and inner stripe of the outer medulla), and papilla
scanning confocal microscope (Bio-Rad Laboratories)(inner medulla). Then, kidney zones and whole kidneys
equipped with a krypton/argon laser and a Axiovert 135were snap-frozen in liquid nitrogen and stored at –80C.
TV microscope (Carl Zeiss, Inc., Oberkochen, Ger-
Protein immunoblot many). Fluorescence was detected with a 585 nm long-
pass filter. Laser settings were identical for acquisitionFor Western blot analysis, frozen whole kidneys were
of images from day 1, 3, 7, and 14 of l-Arg and clampinghomogenized using a stainless steel mortar cooled by
group as well as specimens of sham group. For semiquan-liquid nitrogen, dissolved in lysis buffer containing 25
titative evaluation of superoxide formation, four to sixmmol/L Tris-HCl, 7 mmol/L reduced glutathione, 0.5
images of each treatment group were analyzed densito-mmol/L ethylenediaminetetraacetic acid (EDTA), 0.2
metrically using the Quantity One software (Bio-Radmol/L phenylmethylsulfonyl fluoride (PMSF), 1 mol/L
Laboratories). To describe variation of fluorescence in-leupeptin, 1 mol/L pepstatin, 1 mol/L trans-epoxysuc-
tensity, values were expressed as the percentage of the
cinyl-L-leucylamido butane, and 1 mg/mL trypsin inhibi- respective sham group.
tor, and further minced with an ultrasonic disperser
UW 70 (Bandelin Electronic, Berlin, Germany). For Statistical analysis
analysis of expression of cGMP-dependent protein ki- Data are expressed as mean  standard error of the
nase, different kidney zones, dissected into cortex and mean (SEM). Statistical analysis between experimental
medulla, were used. Total protein was measured in sam- groups was performed by applying the t test for unpaired
ples using the Bradford method [26]. Samples of protein groups. In Figures 1, 2B, 3, 4, 5, and 6, “sham” was set
(5 to 40 g) were analyzed by Western blot with the to 100%, and data of the treatment groups “clamping”
respective antibodies. Rabbit iNOS polyclonal antibody and “clamping l-Arg” are expressed as variation from
(diluted 1:1000) and mouse eNOS monoclonal antibody “sham.” The N value refers to the number of animals
(diluted 1:250) were from Transduction Labaratories used in the experiments. A probability value P 	 0.05
was considered statistically significant.(Lexington, KY, USA); cGK-I polyclonal antibody (di-
Schneider et al: l-Arginine in ischemic acute renal failure 219
rate was below 5% in all treatment groups (data not
shown).
GFR and RPF in the course of ischemic ARF
Inulin clearance was measured to calculate GFR, and
PAH clearance to estimate RPF. In the clamping group,
there was a strong decline in inulin (Fig. 1A) and PAH
clearance (Fig. 1B) when compared to sham group, with
a minimum on day 1 of the follow-up period after isch-
emic ARF (inulin clearance, 0.28  0.11 mL/min/100 g
body weight in clamping group vs. 0.8  0.25 mL/min/
100 g body weight in sham group; PAH clearance, 0.15
0.13 mL/min/100 g body weight in clamping group vs.
1.88  0.55 mL/min/100 g body weight in sham group).
During the following days, GFR and RPF improved in
a nearly linear manner to reach 73.5% of inulin clearance
of sham group on day 14, and 58.0% of PAH clearance
of sham group on day 11 (Fig. 1). In l-Arg–substituted
animals, inulin and PAH clearances were also lowest on
day 1 after induction of ischemic ARF, but significantly
improved during the 14 days of follow-up when com-
pared to clamping group (Fig. 1). In contrast, application
of the stereoisomeric d-Arg had no influence on inulin
and PAH clearances compared to clamping group (data
not shown).
Superoxide radical detection
Impaired renal function during the course of ischemic
ARF could partly result from increased oxidative stress.
We therefore attempted to directly measure oxygen radi-
Fig. 1. Functional parameters in ischemic acute renal failure (ARF)— cal formation in renal tissue. By use of confocal micros-
Impact of L-arginine (L-Arg) supplementation. Line graph shows the copy, kidney sections of clamping group demonstratedcourse of ischemic ARF under l-Arg supplementation (dotted line) on
a marked increase in cortical EtBr fluorescence, with theinulin clearance (A ) and on paraaminohippuric acid (PAH) clearance
(B ) compared to clamping group (gray line) during a 14-day postinter- highest intensity at the first day after intervention and
ventional follow-up. Data of the treatment groups “clamping” and a gradual decrease during follow-up, reflecting an in-“clamping l-Arg” are expressed as variation from “sham.” *P	 0.05
crease in O2 . l-Arg supplementation lowered EtBr fluo-clamping group vs. l-Arg group, N  5 to 8 animals for each individual
time point. rescence at all time points. EtBr fluorescence was lowest
in sham-treated animals (Fig. 2 A). A semiquantitative
evaluation of superoxide formation is presented in Fig-
RESULTS
ure 2 B. Combining histologic and fluorescence pictures
Pharmacokinetics and effects on blood pressure of animals evaluated on day 1 revealed that fluorescence
intensity was highest in tubular structures, while it wasTo rule out NOS-independent effects resulting from
protein supplementation, the stereoisomeric d-Arg was less pronounced in glomerula or interstitial matrix (Fig.
2 C). EtBr fluorescence was distinctly stronger in corticalused in the same manner as described for l-Arg.
In order to compensate for the longer plasma half- kidney segments compared to medullary segments in all
groups analyzed (data not shown).life of d-Arg in comparison to l-Arg, as detected in
preliminary experiments, the intraperitoneally used d-Arg
Expression of NOSdose was adjusted to 125 mg/kg body weight (vs. 500
mg/kg body weight l-Arg), resulting in comparable se- Expression of NOS, particularly the balance of iNOS
and eNOS, are considered to play a major role in therum concentrations (Table 1). The equivalent dose for
oral application of d-Arg was adjusted to 0.125% (vs. course of ischemic ARF. Evaluating exemplary days dur-
ing follow-up after initiation of ischemic ARF, we de-1% l-Arg).
Values of MAP and heart rate were recorded continu- tected a fourfold and, compared to sham, significant up-
regulation of iNOS, peaking on day 1 (Fig. 3). Expressionously for 6 hours. MAP and heart rate were not influ-
enced by l-Arg or d-Arg supplementation, and mortality of iNOS in l-Arg–treated animals was also stronger com-
Table 1. Arginine serum concentrations after intraperitoneal and oral application of l-arginine (l-Arg) and d-arginine (d-Arg)
Time after application
Substance Treatment dose Control 30 minutes 60 minutes 120 minutes 240 minutes 360 minutes
Serum concentration mg/dLSEM
Intraperitoneal
l-Arg 500 mg/kg 2.81.9 21.315 12.58.8 5.33.7 2.51.8 1.30.9
d-Arg 500 mg/kg 1.81.2 44.531 31.021 21.315 9.06.4 5.84.1
d-Arg 125 mg/kg 2.31.6 14.810 14.810 11.58.1 6.34.4 3.32.3
Oral
l-Arg 500 mg/kg 2.01.4 4.83.4 2.51.8 2.01.4 1.51.1 1.00.7
d-Arg 500 mg/kg 2.31.6 10.57.4 14.09.9 15.311 12.08.5 8.86.2
d-Arg 62.5 mg/kg 2.51.8 3.32.3 3.32.3 3.32.3 3.01.2 3.52.5
Fig. 2. Influence of L-arginine (L-Arg) supplementation on superoxide radical generation visualized by ethidiumbromide (EtBr) fluorescence. (A )
Representative confocal laser microscopy (magnification 100 
 1) fluorescence scanning images of cortical kidney specimen of sham (S), clamping
(C), and clamping l-Arg group (C LA) (arranged in lines) on days 1, 3, 7, and 14 after ischemic acute renal failure (ARF). (B ) Semiquantitative
evaluation of superoxide formation by densitometrical detection of fluorescence intensity on days 1, 3, 7, and 14 after ischemic ARF. (C )
Representative images of the histologic tissue structure (a), fluorescence image (b), and an overlay picture of both (c) on the first day of follow
up after ischemic ARF for sham (S), clamping (C), and clamping  l-Arg and group (C  LA) (arranged in lines; magnification 100 
 1).
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Fig. 3. Impact of L-arginine (L-Arg) supplementation on inducible ni- Fig. 4. Impact of L-arginine (L-Arg) supplementation on the expression
tric oxide synthase (iNOS) expression in ischemic acute renal failure of endothelial nitric oxide synthase (eNOS). (A ) Representative West-
(ARF). (A ) Representative Western blot analysis of iNOS expression ern blot analysis of eNOS expression in whole kidney homogenates of
in whole kidney homogenates of clamping group (top line) and l-Arg clamping group (top line) and l-Arg group (bottom line) in a 14-day
group (bottom line) at the time points 1, 3, 7, and 14 days after ischemic follow up after ischemic acute renal failure (ARF). (B ) Effect of l-Arg
ARF. (B ) Effect of l-Arg supplementation on iNOS expression com- supplementation on eNOS expression compared to clamping group
pared to clamping group during 14 days of follow-up after ischemic during 14 days of follow-up after ischemic ARF. Data of the treatment
ARF. Data of the treatment groups “clamping” and “clamping  groups “clamping” and “clamping l-arginine” are expressed as varia-
l-arginine” are expressed as variation from “sham.” *P	 0.05 clamping tion from “sham.” *P 	 0.05 clamping group vs. l-Arg group, N  5
group vs. l-Arg group, N  3 animals for each individual time point. to 8 animals for each individual time point.
of soluble guanylyl cyclase  were detected for solublepared to sham, albeit the increase in expression was only
guanylyl cyclase  (data not shown).1.6-fold.
eNOS was slightly up-regulated on the first days after
Expression of cGK-Iintervention (Fig. 4) with a significantly decreased eNOS
In order to analyze whether soluble guanylyl cyclaseexpression in l-Arg group when compared to clamping
up-regulation affected the signaling cascade downstreamgroup on the second day of follow-up. In the second
of the nitric oxide/cGMP pathway, we measured theweek of postinterventional follow-up, there was a trend
expression of cGMP-dependent protein kinases, cGK-Ifor down-regulation of eNOS, albeit this did not reach
and cGK-II. Cortical and medullary expression of cGK-I,statistical significance (0.05	 P	 0.1) (Fig. 4). A repre-
as well as expression of cGK-II in the clamping group,sentative Western blot analysis of eNOS expression in
did not differ from sham group and was not influencedboth treatment groups clamping and l-Arg is depicted
by l-Arg treatment during the follow-up after ischemicin Figure 4.
ARF (representative blots of cortical cGK-I expression
are depicted in Fig. 6).Expression of soluble guanylyl cyclase after
ischemic ARF
Increased O2 formation, together with an imbalance DISCUSSION
in the expression of iNOS and eNOS, might lead to a We established an animal model of ischemic ARF and
functional nitric oxide deficiency in ischemic ARF [29]. closely monitored several parameters of renal function
In order to evaluate this hypothesis, we measured expres- over a prolonged follow-up period of 14 days. Further-
sion of the nitric oxide receptor soluble guanylyl cyclase. more, we analyzed potential biochemical mechanisms
Ischemic ARF resulted in an upregulation of soluble involved in renal ischemia/reperfusion (I/R) injury. Par-
guanylyl cyclase  expression, with a maximal expression ticular emphasis was placed on the nitric oxide pathway
on day 11 in the clamping group (Fig. 5). l-Arg treatment and on oxidative stress. Finally, the impact of l-Arg
significantly prevented upregulation of soluble guanylyl supplementation on renal function and biochemical mark-
cyclase. Representative Western blots of soluble guany- ers of nitric oxide signaling was investigated.
lyl cyclase expression during the follow-up period are Our model of ischemic ARF resulted in a significant
and, over 14 days, partly reversible reduction of GFRshown in Figure 5. Similar changes as in the expression
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Fig. 5. Influence of L-arginine (L-Arg) supplementation on soluble gua-
nylate cyclase expression in ischemic acute renal failure (ARF). (A )
Western blot analysis of soluble guanylate cyclase  expression in whole Fig. 6. Effect of L-arginine supplementation on cyclic guanosine mono-
kidney homogenates of clamping group (top line) and l-Arg (bottom phosphate (cGMP)-dependent kinase I (cGK-I) expression in ischemic
line) in a 14-day follow-up after ischemic ARF. (B ) Effect of l-Arg acute renal failure (ARF) in cortex and medulla. (A ) Western blot
supplementation on the expression of soluble guanylate cyclase  com- analysis of cortical cGK-I expression of sham group (S), clamping group
pared to clamping group during 14 days of follow-up after ischemic ARF. (C), and clamping and l-Arg group (C  LA) at the time points 1, 3,
Data of the treatment groups “clamping” and “clamping  l-arginine” 7, and 14 days after ischemic ARF. (B ) Effect of l-Arg supplementation
are expressed as variation from “sham.” *P 	 0.05 clamping group vs. on the expression of cGK-I in cortex compared to clamping group
l-Arg group, N  5 to 8 animals for each individual time point. during 14 days of follow-up after ischemic ARF. Data of the treatment
groups “clamping” and “clamping l-arginine” are expressed as varia-
tion from “sham.” N  3 animals for each individual time point.
and RPF. Laser scan microscopy using the fluorescent
dye hydroethidine indicated enhanced in situ O2 forma- course of ARF [30], and the balance of iNOS and eNOS
tion, predominantly in the renal cortex. Enhanced O2 plays an important role [29]. In particular in the setting
formation was indirectly confirmed by enhanced expres- of concomitant oxidative stress [29], as it was the case
sion of nitrotyrosine. This was associated with an early in our experiments, nitric oxide derived from iNOS up-
up-regulation of iNOS, a late moderate decrease in regulation will react with O2 , and significant amounts
eNOS expression, and a continuous rise in expression of peroxynitrite (ONOO) will be formed [31], leading
of the nitric oxide receptor soluble guanylyl cyclase, sug- to nitrosative stress [29]. Indeed, iNOS-dependent NT
gestive for substantial nitric oxide deficiency. Expression formation has been shown in other I/R models (e.g., of
of cGK-I was not altered. l-Arg supplementation im- the brain [32], and enhanced NT formation has been
proved the recovery phase of renal failure, lowered corti- found frequently in ARF [30, 33, 34]).
cal O2 formation, prevented almost completely up-regu- Our general interpretation is that renal ischemia leads
lation of soluble guanylyl cyclase and of iNOS, and to decreased nitric oxide bioavailability, despite initial
prevented partly up-regulation of NT. up-regulation of iNOS. This assumption is based primar-
These results further corroborate and extend that the ily on the up-regulation of the nitric oxide receptor solu-
nitric oxide pathway is fundamentally altered in ARF ble guanylyl cyclase during the recovery phase of isch-
[4, 5]. Previous studies examined short-term I/R injury; emic ARF, together with the moderate down-regulation
our present experimental design allowed observations of eNOS and the beneficial effect of l-Arg. In this con-
over a prolonged period of time. Here we show that text, one has to distinguish between nitric oxide derived
alterations of the nitric oxide pathway take place not from constitutive eNOS and from the iNOS. While
only during the acute phase of ARF, but rather last until eNOS-derived nitric oxide is believed to be responsible
the end of the recovery phase. In particular, our findings for maintaining physiologic renal hemodynamics and
indicate that it is important to differentiate between ini- functions, iNOS-derived nitric oxide predominantly elic-
tial changes and resulting consequences for the recovery its pathologic effects [35]. Thus, even under the condition
phase. Up-regulation of iNOS is an early event that may of up-regulated iNOS, there may be a relative nitric
lead temporarily to increased levels of nitric oxide. In oxide deficiency at sites of physiologic nitric oxide action.
contrast to eNOS-derived nitric oxide, nitric oxide pro- It is commonly accepted that in states of nitric oxide
deficiency soluble guanylyl cyclase sensitivity is up-regu-duced by the iNOS seems to be causally linked to the
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lated [36, 37]. Decreased nitric oxide activity in the proximal tubular cells in terms of lactate dehydrogenase
(LDH) release after hypoxia/reoxygenation [49], and in-course of ARF has been described in various short-term
experimental models [22, 38, 39]. Our observation of a creased lipid peroxidation after l-Arg infusion has also
been observed [50]. In the study by Schramm et al [22],potent up-regulation of soluble guanylyl cyclase in the
follow-up period emphasizes the importance of a relative using a model of toxic ARF, tissue l-Arg levels were
reduced, but still clearly above the Km value for satura-nitric oxide deficiency in ischemic ARF.
Nitric oxide deficiency may result from decreased for- tion of NOS [22]. However, supplementation of l-Arg
had beneficial effects for kidney function, describing themation or increased degradation. The results of our pres-
ent study provide evidence for both mechanisms. It has so-called “l-Arg paradox” [23]. Various mechanisms
have been discussed for this perplexing effect of l-Argbeen suggested that the balance between expression and
activity of the inducible and constitutive isoforms of NOS [23]. Those include compartmentalization of the l-Arg
pool in the cytoplasm, leading to lower concentrationsis disturbed in ARF, and that these changes contribute
to ARF pathophysiology [35]. In particular, up-regula- in vicinity to the eNOS than expected from levels in
tion of iNOS may lead to down-regulation of eNOS [40]. the serum or tissue homogenates. A recent study by
Our data showing initial up-regulation of iNOS shortly McDonald et al [51] indicates that eNOS is colocalized in
after induction of ischemic ARF confirm previous re- cytoplasmic membrane caveolea with the cationic amino
ports [34, 41]. The moderate down-regulation of eNOS acid transporter 1 (CAT-1). As a result, extracellular
may be a consequence of iNOS up-regulation and is well l-Arg might be utilized rapidly by eNOS in such a micro-
in line with the hypothesis of an imbalance between environment, and tissue or serum levels of l-Arg do not
eNOS and iNOS in ischemic ARF. necessarily reflect the substrate pool available for the
However, increased inactivation of nitric oxide may enzyme. This may be of particular relevance in the setting
also be relevant for our observations. As outlined above, of ischemic ARF, since it has been shown recently that
nitric oxide rapidly reacts with O2 , resulting in the forma- mRNA of CAT-2, another cationic amino acid trans-
tion of the highly reactive oxidant ONOO [31] and porter, is up-regulated in ischemic ARF, leading to aug-
scavenging of nitric oxide [42]. ONOO itself is capable mented l-Arg transport [52]. Alternatively, the NOS in-
of causing lipid peroxidation and DNA damage. O2 rep- hibitory effect of asymmetric dimethylarginine (ADMA),
resents an important member of the reactive oxygen an endogenous molecule that accumulates in renal fail-
species (ROS) family, and its formation during I/R injury ure [53], could be overcome by excess l-Arg. Further-
has been demonstrated frequently [43]. Potential sources more, relative l-Arg deficiency could result in an uncou-
for enhanced O2 formation in the kidney are nicotin- pling of NOS, leading to O2 formation instead of nitric
amide adenine dinucleotide phosphate (NADPH) oxi- oxide, as it has been described for tetrahydrobiopterin
dases (Nox) [44], xanthine oxidase (XO) [45] or, in case deficiency [54]. The fact that l-Arg lowered cortical
of l-Arg deficiency, uncoupled NOS itself [46]. Another O2 formation in our model is well in line with this inter-
factor that might contribute to enhanced oxidative stress pretation.
in inschemic ARF has been reported in experimentally
induced renal warm ischemia. In this rat model, enzy-
CONCLUSIONmatic activity of various antioxidants [superoxide dismu-
tase (SOD), glutathion peroxidase, catalase] was signifi- Ischemic ARF is accompanied by marked alterations
cantly reduced [47]. in the expression of key enzymes of the nitric oxide
The beneficial effect of the nitric oxide precursor l-Arg pathway, indicative for deficiency of constitutive NOS
on the course of ischemic ARF provides the third line activity. l-Arg supplementation reduces O2 generation
of evidence for a functional nitric oxide deficiency. l-Arg and significantly improves the expression of nitric oxide
not only improved GFR and RPF, but prevented almost signaling proteins as well as the recovery phase of isch-
completely the up-regulation of soluble guanyclyl cyclase emic ARF.
and of iNOS, partially the up-regulation of NT, and re-
duced O2 formation. This is suggestive for a relative ACKNOWLEDGMENTS
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